Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
-
3,433 Companies
Life science companies in Virginia.
-
$8B Industry
Life Science contributes $8B to Virginia's economy.
-
30, 504 People
Employed by Life Science companies in Virginia.
-
$107,281 Average Wage
Average earnings of life science workers in Virginia.
-
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
News
10/28/2026
U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds
Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …
10/26/2026
ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies
ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …
10/26/2026
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …
Our Premium Partners
